The concordance, sensitivity and specificity of EGFR mutation status by high-performance assays between plasma cfDNA and re-biopsy tisssue-derived tumor DNA in eight NSCLC patients who were performed re-biopsy. This evidence concerns the gene EGFR and neoplasm.